CCN3-derived peptide BLR-200 impairs YAP activation and attenuates bleomycin-induced skin fibrosis through blocking the generation of Sfrp2-positive fibroblasts
John Nguyen, Alexander Peidl, Pratyusha Chitturi, Shannon D. McClintock, Randall Knibbs, Zestranjyan Kannan, Bahja Ahmed Abdi, Connor Denomy, Pashupati Bhandari, David E. Carter, Mathieu Petitjean, John Varga, Dinesh Khanna, Richard J. Stratton, Mohammed Nadeem Aslam, , Andrew Leask
This paper identifies BLR-200, a CCN3-derived peptide, as an anti-fibrotic agent that impairs YAP activation and reduces bleomycin-induced skin fibrosis by blocking Sfrp2-positive fibroblast generation.
bioRxiv · Jul 8, 2026 · PreprintCell Biology